StocksMedium•16 November 2026•
1 min read
Blackstone to Fund Johnson & Johnson Eye Disease R&D for $750M
Key Facts
1Blackstone Life Sciences funds will provide $750 million in development funding to Johnson & Johnson for Phase 3 clinical development of OLN324.
Blackstone Life Sciences funds will provide $750 million in development funding to Johnson & Johnson for Phase 3 clinical development of OLN324. Business Wire reported that the R&D funding agreement is designated to finance the clinical program for the drug, which targets retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema.
Johnson & Johnson closed at $285.75 on November 13, 2026, while Blackstone closed at $120.19 on the same date. The collaboration aims to advance the development of specialized treatments while mitigating capital expenditure risks for Johnson & Johnson in mega-cap pharma projects.